FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer

The prognosis of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer has considerably improved. However, no reliable treatment besides anti-HER2 strategies has been available. FTY720, a small-molecule compound used for treating refractory multiple sclerosis, has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Wei-Pang, Huang, Wei-Lun, Liao, Wei-An, Hung, Chun-Hua, Chiang, Chi-Wu, Cheung, Chun Hei Antonio, Su, Wu-Chou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742024/
https://www.ncbi.nlm.nih.gov/pubmed/34997132
http://dx.doi.org/10.1038/s41598-021-04328-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742024/
https://www.ncbi.nlm.nih.gov/pubmed/34997132
http://dx.doi.org/10.1038/s41598-021-04328-y

Ejemplares similares